rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1552 participants.

Also called NCT05700591

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,552 participants (enrolled count) (from the registry)
Sponsor
Tasly Biopharmaceuticals Co., Ltd. (from the registry)
Registry
  • NCT NCT05700591
Other papers using this trial's data
  • Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial The Lancet. Neurology, 2025-01 DOI, PubMed 39617030

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05700591. Randomized; single masking; primary purpose treatment. Start 2023-01-29 (actual); primary completion 2024-03-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Acronym
PROST-2
Condition
Acute Ischemic Stroke
Intervention (Drug)
rhPro-UK
Intervention (Drug)
rt-PA
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05700591
Content hash
f26710cbbb14617f1965f2ef8750aca8525114592f421796c9457130600558e0